[{"id":"treet-histo","name":"Histological remission at Week 24 (peak eos ≤6/hpf)","type":"CO_PRIMARY","unit":"%","results":[{"notes":"60% achieved histological remission vs 5% placebo","value":60,"arm_id":"dupixent-eoe-treet","p_value":"<0.001","arm_name":"Dupilumab"},{"value":5,"arm_id":"placebo-eoe-treet","arm_name":"Placebo"}],"timepoint":"Week 24","description":"Proportion achieving peak eosinophil count ≤6 per high-power field on esophageal biopsy. Normal esophagus has 0 eosinophils; EoE is defined as ≥15/hpf. Threshold of ≤6 represents near-complete histological resolution."},{"id":"treet-dss","name":"Change in Dysphagia Symptom Questionnaire (DSQ) at Week 24","type":"CO_PRIMARY","unit":"points","results":[{"notes":"LS mean difference vs placebo: -21.9 (p<0.001)","value":-21.9,"arm_id":"dupixent-eoe-treet","arm_name":"Dupilumab"},{"value":-9.6,"arm_id":"placebo-eoe-treet","arm_name":"Placebo"}],"timepoint":"Week 24","description":"Change from baseline in dysphagia (swallowing difficulty) symptom score. Lower = less difficulty. DSQ measures frequency and severity of trouble swallowing solid foods."}]
TREET (n=321, 24 weeks): ISR 10% vs 5%, nasopharyngitis 9% vs 9%. Consistent with known Dupixent safety profile. No new signals in EoE population.
TREET was practice-changing — 60% histological remission vs 5% is a massive effect size. EoE patients previously had no approved therapy and relied on elimination diets and swallowed steroids. The dual endpoint (histology + symptoms) was important because histological improvement without symptom relief would not be meaningful clinically.
EoE is driven by type 2 inflammation with eosinophil infiltration of esophagus, causing dysphagia, food impaction, and strictures. Only prior option was off-label topical steroids.